• 3:00-3:30 PM Networking & Registration
• 3:30-5:00 PM Investor Panel: "Trends in Financing - Looking Back, Looking Ahead"
• 5:00-6:30 PM Networking Reception & Holiday Celebration
The first key to get funding is to understand where the money is. Join experts from the Investment world at our annual “Trends in Financing Panel & Holiday Party” to understand the types of financings that are occurring in your industry today– including topics such as who is getting funding, current valuations and other terms, what investors are looking for, what criteria they use to evaluate and eventually fund your company, etc. – and what is new and what to expect for 2009.
• Samuel D. Colella, Co-Founder and Managing Director, Versant Ventures Click Here for Bio»
• Ellen Koskinas, Partner, InterWest Partners LLC Click Here for Bio»
• Ted Driscoll, Board Director, Sand Hills Angels, & Venture Partner, Claremont Creek Ventures Click Here for Bio»
• Lead Facilitator: Scott M. Iyama, Corporate Lawyer, Emerging Companies Group Member, Orrick, Herrington & Sutcliffe LLP Click Here for Bio»
Samuel D. Colella, Co-Founder and Managing Director, Versant Ventures
A highly respected venture capitalist recognized for his leadership in life sciences investing, Sam Colella co-founded Versant Ventures with six other managing directors in 1999. Over the course of his career, Mr. Colella has acquired more than 20 years of successful operating experience in the high technology industry and more than 25 years of investing experience in the healthcare sector.
Prior to founding Versant, Mr. Colella managed one of the first life science-focused investing groups in the industry as a general partner with Institutional Venture Partners (IVP). Previously, he was president of a New York Stock Exchange company and held a variety of functional positions in a broad array of diverse businesses, including president of Spectra-Physics, the world's leading laser supplier, and senior manager of the Technical Products Division of Corning Glass.
Having managed investments concentrated in medical devices, biotechnology and health care technology companies, Mr. Colella is credited with an extensive list of successful public life science companies, including Alexza Pharmaceuticals, Argonaut Technologies, Arthrocare, Athena Neurosciences, Aviron, CV Therapeutics, Endosonics, Genomic Health Inc., IVAC Holdings, Jazz Pharmaceuticals, Onyx Pharmaceuticals, Pharmacopeia, Symyx Technologies, Thermage, Tularik and Vivus. He is currently a director of Alavita, Alexza Pharmaceuticals, EuroVentures, Flexion, Genomic Health Inc., and Jazz Pharmaceuticals, Veracyte, and he is Chairman of Fluidigm, Inc.
Mr. Colella’s professional affiliations include terms of service as an officer in the National Venture Capital Association, the Western Association of Venture Capitalists, and American Entrepreneurs for Economic Growth and Chairman of the Stanford Council on Interdisciplinary Biosciences. Mr. Colella has a B.S. degree in Business and Engineering from the University of Pittsburgh and an M.B.A. degree from Stanford University.
Ellen Koskinas, Partner, InterWest Partners LLC
Ellen Koskinas focuses on life sciences investing, with an emphasis on medical devices. She is a board member of Applied Spine Technologies, Apsara Medical, CardioMind, EnteroMedics and Neuronetics. She has also been an active observer on the boards of Epicor (acquired by St. Jude Medical), NeuroPace and Paracor Medical.
Prior to InterWest, Koskinas held a number of key roles in marketing and business development at Guidant Corporation, where she built a new business in minimally invasive cardiac surgery and then led Guidant's acquisition of CardioThoracic Systems. Koskinas has also served as an Engagement Manager for McKinsey & Company, managing projects for a broad range of pharmaceutical, healthcare delivery and medical device clients. At the outset of her career, she worked in corporate finance at Morgan Stanley in New York and London.
Koskinas received a B.A. in economics with honors from Harvard College and received a M.B.A. from the Stanford Graduate School of Business.
Ted Driscoll, Board Director, Sand Hills Angels, & Venture Partner, Claremont Creek Ventures
Ted Driscoll is a Venture Partner at Claremont Creek Ventures and a Special Limited Partner at Novus Ventures. Over the past two decades, Ted helped found five successful companies in imaging-related markets. He was founder and CEO of Be Here Technologies, a pioneer in Internet, Broadcast and Videoconferencing technologies. He served as a Division President and CTO of Diasonics, with responsibility for its MRI, ultrasound, digital X-ray, lithotripsy and acoustic ablation technology areas. He had earlier directed the technology team that developed the first commercial MRI scanners and numerous advance in MR imaging. Previously, he was Vice President of Engineering and R&D; of Identix, now a world leader in fingerprint and face recognition, and Director of R&D; at International Imaging Systems, an early pioneer in remote sensing. His research and patents in ultrasound therapy and acoustic hemostasis also led to the founding of another company, Therus, now partnered with Boston Scientific.
Ted earned a PhD from Stanford University in Digital Imaging, Masters degrees from Harvard University in Computer Graphics and Remote Sensing, and a Bachelor's degree from the University of Pennsylvania. Ted holds 40+ granted U.S. and foreign patents in image-related fields, with approximately 30 additional pending applications.
Lead Facilitator: Scott M. Iyama, Corporate Lawyer, Emerging Companies Group Member, Orrick, Herrington & Sutcliffe LLP
Scott Iyama, a corporate attorney in Orrick's Silicon Valley office, is a member of the Emerging Companies Group, which advises emerging companies and venture capital firms. Mr. Iyama's practice focuses on the representation of emerging growth life science and high tech companies, as well as public offerings, private venture financings, and technology transactions. A representative list of Mr. Iyama's clients include CellPoint Dialogistic, Facebook, Greenplum, Laserscope, Micrus Endovascular and SquareOne. Mr. Iyama has also represented Benchmark Capital, De Novo Ventures, Kleiner Perkins Caufield & Byers, Maveron, Montreux Equity Partners, Telegraph Hill Partners in various investments. Prior to receiving his J.D. from Stanford Law School, Mr. Iyama received a M.S. and B.S in Biochemistry/Cell Biology from the University of California, San Diego. Mr. Iyama also performed extensive research at Genentech, Inc. and the NASA/Ames Research Center.
The San Jose BioCenter
5941 Optical Court
San Jose, CA 95138
Click here for Venue Directions»